Lantern Pharma, Inc. (LTRN)
Stock Price:
$16.47 USD
-0.35 (-2.08%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
102.40M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
6.22M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$16.47 |
| Previous Close |
$16.82 |
| Change ($) |
-0.35 |
| Change (%) |
-2.08% |
| Day's Open |
16.82 |
| Day's Range |
16.10 - 17.49 |
| Day's Volume |
85,245 |
| 52-Week Range |
10.40 - 19.50 |
More Stats
| Market Cap |
102.40M |
| Enterprise Value |
78.82M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
6.22M |
| Float |
2.29M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3,161 |
| Short Ratio |
0.43 |
| Short % of Float |
0.92% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.74 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
23.59M |
| Net Cash / Share |
3.79 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$24.50*
(48.76% upside)
Low
24.0
Current: $16.47
High
25.0
Target: 24.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -2.43 | -1.73 |
| Net Income | -2.43 | -1.73 |
| Shares Outstanding | 1.14 | 1.11 |
| Earnings Per Share | -2.14 | -1.56 |
| Operating Cash Flow | -2.13 | -1.27 |
| Capital Expenditures | -0.01 | 0.01 |
| Free Cash Flow | -2.13 | -1.27 |
| Cash & Equivalents | 1.23 | 0.45 |
| Net Cash / Debt | 1.23 | 0.45 |
| Assets | 1.43 | 0.45 |
| Liabilities | 0.49 | 0.65 |
| Book Value | 0.94 | -0.20 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Lantern Pharma, Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Panna L. Sharma |
Stock Information
| Ticker Symbol |
LTRN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LTRN |
| IPO Date |
June 11, 2020 |
Description
Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. Address: 1920 McKinney Avenue, Dallas, TX, United States, 75201